Alk-Abello As B Shs New (AKBLF) Q3 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Alk-abello A/s Class B.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.723 -- 00:00:05.731 Hello and welcome to this presentation of ALK's Q3 results and full year outlook. 00:00:05.731 -- 00:00:10.058 And thank you all for joining us. Let's turn to slide number two with the agenda and 00:00:10.058 -- 00:00:11.700 speakers. 00:00:11.700 -- 00:00:14.565 My name is Pierre Klotnikoff. I'm Head of Investor Relations. 00:00:14.565 -- 00:00:20.214 And with me today are CEO Peter Helling and CFO Klaus Steinsen-Sølje. 00:00:20.214 -- 00:00:24.140 We'll first share a couple of quarterly highlights, followed by a closer look at markets, 00:00:24.140 -- 00:00:29.261 products and financials. We will detail some of our strategic focus areas before we cover 00:00:29.261 -- 00:00:34.428 the new full year outlook. As usual, we will end the presentation with a Q&A session. 00:00:34.428 -- 00:00:38.654 And to get us started, I'll hand over to Peter and slide number three. 00:00:38.654 -- 00:00:40.757 Please go ahead, Peter. 00:00:40.757 -- 00:00:45.163 Thank you, Per, and thank you all for joining this call. 00:00:45.163 -- 00:00:51.230 Q3 was characterized by a strong focus on execution of our key strategic initiatives. 00:00:51.230 -- 00:00:55.834 The pediatric tablet launches a new partnership for China and the commercialization of 00:00:55.834 -- 00:00:57.556 NEFI. 00:00:57.556 -- 00:01:01.680 Market responses to the tablet launches for children are truly encouraging. 00:01:01.680 -- 00:01:06.304 The rollout of the HowStuffMyTablet Acarisax for children progressed well and continues 00:01:06.304 -- 00:01:10.168 to contribute to the inflow of new patients in Q3. 00:01:10.168 -- 00:01:15.593 Moreover, Acarisax is attracting new prescribers, not least amongst pediatricians, 00:01:15.593 -- 00:01:20.217 suggesting that the children indica...